Revelation Biosciences Completes Enrollment And Dosing In First Human Phase 1 Study Of Gemini; Top-Line Data To Include Safety, Tolerability, And Biomarkers; Supports Future Development Across Multiple Indications
Revelation Biosciences Completes Enrollment And Dosing In First Human Phase 1 Study Of Gemini; Top-Line Data To Include Safety, Tolerability, And Biomarkers; Supports Future Development Across Multiple Indications
启示生物科技完成“双子座”第一阶段人类试验的招募和给药，顶线数据将包括安全性、耐受性和生物标志物；支持未来在多个适应症领域的发展。
Revelation Biosciences Completes Enrollment And Dosing In First Human Phase 1 Study Of Gemini; Top-Line Data To Include Safety, Tolerability, And Biomarkers; Supports Future Development Across Multiple Indications
Revelation生物科技完成Gemini第一阶段人体试验的招募和投药；首要数据将包括安全性、耐受性和生物标志物；支持未来在多种适应症中的发展。